<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613417</url>
  </required_header>
  <id_info>
    <org_study_id>PH-107</org_study_id>
    <nct_id>NCT01613417</nct_id>
  </id_info>
  <brief_title>Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain</brief_title>
  <acronym>TRUTH</acronym>
  <official_title>Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at a direct comparison between ProHance (0.1 mmol/kg) and a validated
      comparator Gadovist/Gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects
      with brain tumors to confirm the identical overall technical and diagnostic performance of
      the two MR contrast agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients were given two MRI exams, one after injection of ProHance (0.1 mmol/kg) and
      one after injection of Gadovist/Gadavist (0.1 mmol/kg). The exams were performed with
      identical equipment and imaging parameters with the order of the two exams randomized and
      2-14 days between the first and the second MRI exam. Image data was evaluated by 3 expert
      neuroradiologist blinded to the agent administered and patient clinical data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Diagnostic Preference Between the Two Exams</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion Border Delineation</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Internal Morphology</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of Disease</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Contrast Enhancement</measure>
    <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
    <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion to Background Ratio on Post T1-weighed Spin Echo Images</measure>
    <time_frame>5-10 minutes Postdose</time_frame>
    <description>Mean of difference in signal intensity postdose (ProHance - Gadovist/Gadavist)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Signal Intensity Enhancement on Postdose Images</measure>
    <time_frame>5-10 minutes Postdose</time_frame>
    <description>Mean difference in percentage signal intensity enhancement on postdose T1-weighted SE/FSE images (ProHance - Gadovist/Gadavist)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Detection</measure>
    <time_frame>5-10 minutes Postdose</time_frame>
    <description>Lesion detection rate by contrast agent and reader</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy for Tumor Characterization</measure>
    <time_frame>5-10 minutes Postdose</time_frame>
    <description>Blinded reader assessment of accuracy of tumor characterization (benign/malignant) - patient level assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Brain Disease</condition>
  <arm_group>
    <arm_group_label>MRI with Gadoteridol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRI after 0.1 mmol/kg IV ProHance, then with 0.1 mmol/kg Gadovist/Gadavist. MRI performed after both agents with identical sequences.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI with Gadobutrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRI after 0.1 mmol/kg IV Gadovist/Gadavist, then with 0.1 mmol/kg ProHance. MRI performed after both agents with identical sequences.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadoteridol</intervention_name>
    <description>ProHance 0.1 mmol/kg</description>
    <arm_group_label>MRI with Gadoteridol</arm_group_label>
    <arm_group_label>MRI with Gadobutrol</arm_group_label>
    <other_name>ProHance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadobutrol</intervention_name>
    <description>Gadovist/Gadavist 0.1 mmol/kg</description>
    <arm_group_label>MRI with Gadoteridol</arm_group_label>
    <arm_group_label>MRI with Gadobutrol</arm_group_label>
    <other_name>Gadovist, Gadavist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are scheduled to undergo MRI

          -  Are willing to undergo two MRI procedures within 14 days

          -  Have confirmed or are highly suspected of brain disease likely to enhance as
             determined by the following:

          -  Clinical/neurological symptomatology;

          -  Diagnostic testing, such as CT or previous MRI examinations; or

          -  Have had previous brain surgery and are to be evaluated for recurrence.

        Exclusion Criteria:

          -  Are pregnant or lactating females. Exclude the possibility of pregnancy:

          -  by testing on site at the institution within 24 hours prior to the start of each
             investigational product administration; or

          -  by history (i.e., tubal ligation or hysterectomy); or

          -  post menopausal with a minimum of 1 year without menses

          -  Have any known allergy to one or more of the ingredients in the investigational
             products, or have a history of hypersensitivity to any metals

          -  Have congestive heart failure (class IV according to the classification of the New
             York Heart Association; see Appendix A)

          -  Have suffered a stroke within a year

          -  Have received or are scheduled to receive any other contrast medium in the 24 hours
             preceding through the 24 hours following Exam 1, and in the 24 hours preceding through
             the 24 hours following Exam 2

          -  Have received or are scheduled to receive an investigational compound and/or medical
             device within 30 days before admission into the present study, through the 24 hours
             post-administration of the second investigational product.

          -  Have moderate-to-severe renal impairment, defined as a GFR/eGFR &lt; 45 mL/min.

          -  Have been previously entered into this study

          -  Have received or are scheduled for one of the following:

          -  Surgery within three weeks prior to the first examination or between the two
             examinations

          -  Initiation of steroid therapy between the two examinations

          -  Radiosurgery between the two examinations

          -  Have any contraindications to MRI such as a pace-maker, magnetic material (i.e.,
             surgical clips) or any other conditions that would preclude proximity to a strong
             magnetic field.

          -  Are suffering from severe claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianpaolo Pirovano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Žižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study). AJNR Am J Neuroradiol. 2015 Jan;36(1):14-23. doi: 10.3174/ajnr.A4154. Epub 2014 Oct 9.</citation>
    <PMID>25300984</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <results_first_submitted>April 28, 2015</results_first_submitted>
  <results_first_submitted_qc>May 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2015</results_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Have confirmed or are highly suspected of brain disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 229 patients were recruited from September 2012 through November 2013 at 19 clinical trial sites. Off-site assessment of the images was performed between 21 January and 3 April 2014 by 3 board-certified neuroradiologists blinded as to which contrast agent was used, patient clinical information, and the results of other imaging studies.</recruitment_details>
      <pre_assignment_details>229 patients were enrolled and signed informed consent. Each enrolled patient was randomized and dosed with at least one contrast agent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 (ProHance Then Gadovist/Gadavist)</title>
          <description>Patients randomized to receive ProHance first</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2 (Gadovist/Gadavist Then ProHance)</title>
          <description>Patients randomized to receive Gadovist/Gadavist first</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Injection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (no Second Injection/MRI)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Injection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per Protocol</population>
      <group_list>
        <group group_id="B1">
          <title>ProHance Then Gadovist/Gadavist</title>
          <description>Per Protocol=patients who completed both exams, had global paired image data available, and had no major protocol violations</description>
        </group>
        <group group_id="B2">
          <title>Gadovist/Gadavist Then ProHance</title>
          <description>Per Protocol=patients who completed both exams, had global paired image data available, and had no major protocol violations</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="14.27"/>
                    <measurement group_id="B2" value="55.9" spread="14.29"/>
                    <measurement group_id="B3" value="55.2" spread="14.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Diagnostic Preference Between the Two Exams</title>
        <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <population>Per Protocol=patients who completed both exams, had global paired image data available, and had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
            <description>Paired exams reviewed by Reader 1</description>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
            <description>Paired exams reviewed by Reader 2</description>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
            <description>Paired exams reviewed by Reader 3</description>
          </group>
        </group_list>
        <measure>
          <title>Global Diagnostic Preference Between the Two Exams</title>
          <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
          <population>Per Protocol=patients who completed both exams, had global paired image data available, and had no major protocol violations</population>
          <units>participant exams</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient Exams</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ProHance Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Agents Equal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gadovist/Gadavist Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculation was based on primary endpoint. 185 patients were deemed necessary for the lower limit of the observed 2-sided 95% confidence interval for the difference to exceed -5% with 85% power.</non_inferiority_desc>
            <p_value>0.8516</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Percentage PH better minus GV better</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
            <estimate_desc>Difference in percentage ProHance better minus percentage Gadovist/Gadavist better (%)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculation was based on primary endpoint. 185 patients were deemed necessary for the lower limit of the observed 2-sided 95% confidence interval for the difference to exceed -5% with 85% power.</non_inferiority_desc>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Percentage PH better minus GV better</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>Difference in percentage ProHance better minus percentage Gadovist/Gadavist better (%)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculation was based on primary endpoint. 185 patients were deemed necessary for the lower limit of the observed 2-sided 95% confidence interval for the difference to exceed -5% with 85% power.</non_inferiority_desc>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Percentage PH better minus GV better</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Difference in percentage ProHance better minus percentage Gadovist/Gadavist better (%)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Border Delineation</title>
        <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
            <description>Paired exams reviewed by Reader 1</description>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
            <description>Paired exams reviewed by Reader 2</description>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
            <description>Paired exams reviewed by Reader 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Border Delineation</title>
          <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
          <units>participant exams</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient Exams</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ProHance Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Difference between Prohance and Gadovist/Gadavi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gadovist/Gadavist Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Internal Morphology</title>
        <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
            <description>Paired exams reviewed by Reader 1</description>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
            <description>Paired exams reviewed by Reader 2</description>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
            <description>Paired exams reviewed by Reader 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Internal Morphology</title>
          <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
          <units>participant exams</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient Exams</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ProHance better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Difference Between ProHance and Gadovist/Gadavi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gadovist/Gadavist betterB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6875</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Disease</title>
        <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
            <description>Paired exams reviewed by Reader 1</description>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
            <description>Paired exams reviewed by Reader 2</description>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
            <description>Paired exams reviewed by Reader 3</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Disease</title>
          <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
          <units>participant exams</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient Exams</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ProHance Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Difference between ProHance and Gadovist/Gadavi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gadovist/Gadavist Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Contrast Enhancement</title>
        <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
        <time_frame>Comparison of image sets obtained within 2 to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
            <description>Paired exams reviewed by Reader 1</description>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
            <description>Paired exams reviewed by Reader 2</description>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
            <description>Paired exams reviewed by Reader 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Contrast Enhancement</title>
          <description>Assessed by 3 blinded readers for each of the 198 patients who had post-dose exams for both ProHance and Gadovist/Gadavist. Readers assessed whether images with ProHance were preferred or images with Gadovist/Gadavist were preferred, or whether images after both exams were considered equal.</description>
          <units>participant exams</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient Exams</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ProHance Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Difference between ProHance and Gadovist/Gadavi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="174"/>
                    <measurement group_id="O3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gadovist/Gadavist Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P-value from Wilcoxon signed-rank test</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion to Background Ratio on Post T1-weighed Spin Echo Images</title>
        <description>Mean of difference in signal intensity postdose (ProHance - Gadovist/Gadavist)</description>
        <time_frame>5-10 minutes Postdose</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
            <description>Lesions reviewed by Reader 1</description>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
            <description>Lesions reviewed by Reader 2</description>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
            <description>Lesions reviewed by Reader 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion to Background Ratio on Post T1-weighed Spin Echo Images</title>
          <description>Mean of difference in signal intensity postdose (ProHance - Gadovist/Gadavist)</description>
          <population>Per-protocol population</population>
          <units>signal intensity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.17"/>
                    <measurement group_id="O2" value="-0.16" spread="1.12"/>
                    <measurement group_id="O3" value="-0.01" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2758</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with period, sequence, and IP and fixed effect and subject nested within sequence as random effect</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0676</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with period, sequence, and IP and fixed effect and subject nested within sequence as random effect</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5267</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model with period, sequence, and IP and fixed effect and subject nested within sequence as random effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Signal Intensity Enhancement on Postdose Images</title>
        <description>Mean difference in percentage signal intensity enhancement on postdose T1-weighted SE/FSE images (ProHance - Gadovist/Gadavist)</description>
        <time_frame>5-10 minutes Postdose</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
            <description>Lesions reviewed by Reader 1</description>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
            <description>Lesions reviewed by Reader 2</description>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
            <description>Lesions reviewed by Reader 3</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Signal Intensity Enhancement on Postdose Images</title>
          <description>Mean difference in percentage signal intensity enhancement on postdose T1-weighted SE/FSE images (ProHance - Gadovist/Gadavist)</description>
          <population>Per-protocol population</population>
          <units>percentage signal intensity enhancement</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="28.61"/>
                    <measurement group_id="O2" value="-2.09" spread="29.06"/>
                    <measurement group_id="O3" value="-1.59" spread="29.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6201</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4514</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7722</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Investigation product (IP) effect from mixed model with period, sequence, and IP as fixed effects and subject nested within sequence as random effect.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Detection</title>
        <description>Lesion detection rate by contrast agent and reader</description>
        <time_frame>5-10 minutes Postdose</time_frame>
        <population>Per protocol patients with histologically confirmed lesions</population>
        <group_list>
          <group group_id="O1">
            <title>Reader 1 - ProHance</title>
            <description>MRI after ProHance 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>Reader 1 - Gadovist/Gadavist</title>
            <description>MRI after Gadovist/Gadavist 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>Reader 2 - ProHance</title>
            <description>MRI after ProHance 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>Reader 2 - Gadovist/Gadavist</title>
            <description>MRI after Gadovist/Gadavist 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>Reader 3 - ProHance</title>
            <description>MRI after ProHance 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>Reader 3 - Gadovist/Gadavist</title>
            <description>MRI after Gadovist/Gadavist 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Detection</title>
          <description>Lesion detection rate by contrast agent and reader</description>
          <population>Per protocol patients with histologically confirmed lesions</population>
          <units>participant exams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="139"/>
                <count group_id="O5" value="139"/>
                <count group_id="O6" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>True Positive (Patients)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="137"/>
                    <measurement group_id="O4" value="136"/>
                    <measurement group_id="O5" value="136"/>
                    <measurement group_id="O6" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>False Negative (Pa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3173</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5637</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0455</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy for Tumor Characterization</title>
        <description>Blinded reader assessment of accuracy of tumor characterization (benign/malignant) - patient level assessment</description>
        <time_frame>5-10 minutes Postdose</time_frame>
        <population>Subjects with histologically confirmed lesions</population>
        <group_list>
          <group group_id="O1">
            <title>Reader 1 - ProHance</title>
            <description>MRI after ProHance 0.1 mmol/kg</description>
          </group>
          <group group_id="O2">
            <title>Reader 1 - Gadovist/Gadavist</title>
            <description>MRI after Gadovist/Gadavist 0.1 mmol/kg</description>
          </group>
          <group group_id="O3">
            <title>Reader 2 - ProHance</title>
            <description>MRI after ProHance 0.1 mmol/kg</description>
          </group>
          <group group_id="O4">
            <title>Reader 2 - Gadovist/Gadavist</title>
            <description>MRI after Gadovist/Gadavist 0.1 mmol/kg</description>
          </group>
          <group group_id="O5">
            <title>Reader 3 - ProHance</title>
            <description>MRI after ProHance 0.1 mmol/kg</description>
          </group>
          <group group_id="O6">
            <title>Reader 3 - Gadovist/Gadavist</title>
            <description>MRI after Gadovist/Gadavist 0.1 mmol/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy for Tumor Characterization</title>
          <description>Blinded reader assessment of accuracy of tumor characterization (benign/malignant) - patient level assessment</description>
          <population>Subjects with histologically confirmed lesions</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="128"/>
                <count group_id="O5" value="128"/>
                <count group_id="O6" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with Tumors Correctly Categorized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="101"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Tumors Incorrectly Categorized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>McNemar test of difference (ProHance minus Gadovist/Gadavist) in accuracy for tumor characterization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6949</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>McNemar test of difference (ProHance minus Gadovist/Gadavist) in accuracy for tumor characterization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1317</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>McNemar test of difference (ProHance minus Gadovist/Gadavist) in accuracy for tumor characterization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0124</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 hours after contrast media injection</time_frame>
      <desc>All adverse events collected were categorized using MedDRA 16.1 and tabulated</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety Population (ProHance)</title>
          <description>All enrolled patients who received a randomized injection of ProHance</description>
        </group>
        <group group_id="E2">
          <title>Safety Population (Gadovist/Gadavist)</title>
          <description>All enrolled patients who received a randomized injection of Gadovist/Gadavist</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Orophanyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study results may be presented at scientific symposia or published in a peer-review journal after review by sponsor in accordance with the guidelines set forth in the applicable publication or financial agreement</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Histologic confirmation of disease available for only 139/198 patients in the PP analysis. Of these, 128 patients had confirmed brain tumors and were available for the analyses of diagnostic performance (tumor detection and tumor characterization).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gianpaolo Pirovano, MD</name_or_title>
      <organization>Executive Director, MRI</organization>
      <phone>609-514-2226</phone>
      <email>gianpaolo.pirovano@diag.bracco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

